Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kineta Inc (KANT)

Kineta Inc (KANT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Kineta Inc 7683 SE 27TH STREET SUITE 481 MERCER ISLAND WA 98040 USA

https://kinetabio.com Employees: 11 P: 206-378-0400

Description:

Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.

Key Statistics

Overview:

Market Capitalization, $K 8,416
Enterprise Value, $K 2,706
Shares Outstanding, K 12,250
Annual Sales, $ 5,440 K
Annual Net Income, $ -14,100 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,600 K
EBIT, $ -17,260 K
EBITDA, $ -17,250 K
60-Month Beta 0.46
Float, K 10,390
% Float 100.00%
Short Volume Ratio 0.08

Growth:

1-Year Return -23.68%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 91.55%
5-Year Earnings Growth 99.38%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 08/08/24
Next Earnings Date 11/01/24
Earnings Per Share ttm -1.74
EPS Growth vs. Prev Qtr 77.53%
EPS Growth vs. Prev Year -150.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-7 on 12/19/22

KANT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -336.47%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 1.55
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.65
Interest Coverage -40.41
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar